ENDRA Life Sciences Inc. (NDRA) |
| 5.005 -0.405 (-7.49%) 08-28 16:00 |
| Open: | 5.735 |
| High: | 5.74 |
| Low: | 4.8 |
| Volume: | 24,371 |
| Market Cap: | 6(M) |
| PE Ratio: | -0.64 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 6.74 |
| Resistance 1: | 5.77 |
| Pivot price: | 4.67 |
| Support 1: | 4.71 |
| Support 2: | 4.05 |
| 52w High: | 9.85 |
| 52w Low: | 2.96 |
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
| EPS | -6.290 |
| Book Value | 1.440 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -77.3 |
| Return on Equity (ttm) | -152.0 |
Mon, 24 Aug 2026
ENDRA Life Sciences Market Sentiment - Benzinga France
Mon, 24 Aug 2026
ENDRA Life Sciences Inc (NASDAQ:NDRA) - intelligentinvestor.com.au
Fri, 21 Aug 2026
ENDRA (NASDAQ: NDRA) weighs shift into South African helium - Stock Titan
Mon, 17 Aug 2026
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Mon, 17 Aug 2026
ENDRA Life Sciences (Nasdaq: NDRA) shares Q2 2026 earnings update - Stock Titan
Thu, 25 Jun 2026
NDRA Forecast — Price Target — Prediction for 2027 - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |